Search

Your search keyword '"Rouleau J"' showing total 707 results

Search Constraints

Start Over You searched for: Author "Rouleau J" Remove constraint Author: "Rouleau J"
707 results on '"Rouleau J"'

Search Results

1. Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

3. THE RECARDIO TRIAL PROTOCOL: COMPARING THE EFFECTS OF COGNITIVE TRAINING AND PHYSICAL EXERCISE ON COGNITION AND CEREBRAL AUTOREGULATION IN MEN AND WOMEN WITH HEART FAILURE

4. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

5. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

12. History of stroke in patients with heart failure: prevalence, baseline characteristics and clinical outcomes

13. Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial

15. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model

16. Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials

17. Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: insight from PARADISE MI trial

18. PARADISE-MI – event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40

19. A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)

20. Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: insights from PARADIGM-HF

22. Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction

25. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial

28. Abstracts of original contributions ASNC 2004 9th annual scientific session September 3-–October 3, 2004 New York, New York

29. OPTIMIZATION OF EVIDENCE-BASED THERAPIES FOR HEART FAILURE AND REDUCED EJECTION FRACTION PATIENTS IMPROVES OUTCOMES IN AN AMBULATORY SPECIALIZED SETTING

34. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

36. CAN CARE GAPS IN ADHERENCE TO GUIDELINES THERAPY IN AN OUTPATIENT SPECIALIZED HEART FAILURE SETTING BE EXPLAINED BY CLINICAL AND PHYSIOLOGICAL FACTORS RATHER THAN CLINICAL INERTIA

37. P6350Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the spironolactone for heart failure with preserved ejection fraction (TOPCAT) trial

38. P2630Incidence and prognostic impact of new-onset left bundle branch block in patients with heart failure and reduced ejection fraction

39. The continuous heart failure spectrum: Moving beyond an ejection fraction classification

40. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

50. International variations in the gestational age distribution of births: An ecological study in 34 high-income countries

Catalog

Books, media, physical & digital resources